Drug | Dosing Regimen | Efficacy (study reference) | Approved for | Efficacy in PsO (Nast 2012)1 | |
---|---|---|---|---|---|
PsA | PsO | ||||
Methotrexate | 15 mg/week | Mean PASI reduced from 3.76 to 2.2 at 6 mo7 | Yes | Yes | PASI75: 30–50% |
10–25 mg/week | After 6 mo: PASI50: 31% PASI75: 24%8 | ||||
15 mg/week | Mean PASI reduced from 2.2 to 1.9 after 12 mo9 | ||||
16.2 mg/week | PASI50: 57% after 24 mo10 | ||||
15 mg/week | PASI75: 54.3% after 4 mo11 | ||||
7.5–15 mg/week | After 12 mo: Reduction of the mean PASI in overweight patients from 13.1 to 3.05, in normal weight patients from 11.98 to 1.0412 | ||||
15 mg/week IM | Reduction of the mean PASI from 8.2 to 4.3 after 6 mo13 | ||||
Leflunomide | 100 mg/day for 3 days, then 20 mg/day for 6 mo | After 6 mo: PASI50: 30.4% PASI75: 17.4%14 | Yes | No | No published data from PsO trials in the public domain |
Cyclosporine | 2.5–3.75 mg/kg/day for 12 mo | PASI response after 12 mo: PASI50: 65% PASI75: 27.5%15 | No | Yes | PASI75: 50–70% |
3–5 mg/kg/day for 12 mo | Mean PASI reduction of 7.616 | ||||
3 mg/kg/day for 24 mo | Reduction of the mean PASI from 15.1 to 5.217 |
PsO: psoriasis; DMARD: disease-modifying antirheumatic drug; IM: intramuscularly; PASI: Psoriasis Area and Severity Index.